



(12)

# Oversættelse af europæisk patentskrift

Patent- og  
Varemærkestyrelsen

(51)	Int.Cl.:	<b>A 61 P 1/00 (2006.01)</b> <b>A 61 K 31/195 (2006.01)</b> <b>A 61 K 33/04 (2006.01)</b> <b>A 61 K 47/10 (2017.01)</b> <b>A 61 P 9/00 (2006.01)</b> <b>A 61 P 17/00 (2006.01)</b>	<b>A 61 K 9/00 (2006.01)</b> <b>A 61 K 31/7004 (2006.01)</b> <b>A 61 K 33/14 (2006.01)</b> <b>A 61 K 47/26 (2006.01)</b> <b>A 61 P 9/06 (2006.01)</b> <b>A 61 P 31/14 (2006.01)</b>	<b>A 61 K 9/08 (2006.01)</b> <b>A 61 K 31/765 (2006.01)</b> <b>A 61 K 47/02 (2006.01)</b> <b>A 61 P 7/00 (2006.01)</b> <b>A 61 P 9/10 (2006.01)</b> <b>A 61 P 43/00 (2006.01)</b>
(45)	Oversættelsen bekendtgjort den:	<b>2022-02-14</b>		
(80)	Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet:	<b>2021-12-22</b>		
(86)	Europæisk ansøgning nr.:	<b>15767838.4</b>		
(86)	Europæisk indleveringsdag:	<b>2015-03-24</b>		
(87)	Den europæiske ansøgnings publiceringsdag:	<b>2017-02-01</b>		
(86)	International ansøgning nr.:	<b>US2015022198</b>		
(87)	Internationalt publikationsnr.:	<b>WO2015148474</b>		
(30)	Prioritet:	<b>2014-03-25 US 201461970247 P</b>		<b>2014-06-30 US 201462019007 P</b>
(84)	Designerede stater:	<b>AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR</b>		
(73)	Patenthaver:	<b>Leading Biosciences, Inc., 420 Stevens Avenue, Suite 370 Solana Beach, CA 92075 , , USA</b>		
(72)	Opfinder:	<b>RODENRYS, John, 2459 Darlington Row, La Jolla, CA 92037, USA</b> <b>HALLAM, Thomas, 420 Stevens Avenue, Suite 370, Solana Beach, CA 92075, USA</b> <b>JACKMAN, Robin, 8387 Watson Ranch Rd, San Diego, CA 92129, USA</b>		
(74)	Fuldmægtig i Danmark:	<b>NORDIC PATENT SERVICE A/S, Bredgade 30, 1260 København K, Danmark</b>		
(54)	Benævnelse:	<b>SAMMENSÆTNINGER TIL BEHANDLING AF AUTODIGESTION</b>		
(56)	Fremdragne publikationer:	<b>CN-A- 103 099 800</b> <b>CN-A- 103 565 743</b> <b>US-A- 4 465 662</b> <b>US-A1- 2009 017 114</b> <b>US-A1- 2014 271 923</b> <b>US-B1- 6 708 822</b> <b>FRANK A. DELANO ET AL: "Pancreatic Digestive Enzyme Blockade in the Small Intestine Prevents Insulin Resistance in Hemorrhagic Shock", SHOCK, vol. 41, no. 1, 1 January 2014 (2014-01-01), pages 55-61, XP055402808, US ISSN: 1073-2322, DOI: 10.1097/SHK.0000000000000048</b> <b>Omega Standard ET AL: "PRODUCT MONOGRAPH Pr TRANEXAMIC ACID INJECTION 100 mg/mL", , 30 August 2012 (2012-08-30), XP055403121, Retrieved from the Internet: URL:https://www.google.nl/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=3&amp;ved=0ahUKEwjM3eP2 74PWAhUKJ1AKHdSbDgkQFgg7MAI&amp;url=http%3A%2F</b>		

Fortsættes ...

%2Fwww.omegalaboratory.com%2Findex.php%2Fdownload\_file%2Fview%2F2057%2F327%2F&usg=AFQjCNEsPoXurO5oRL9TzyACynv8dI-tnA [retrieved on 2017-09-01]  
None

# DESCRIPTION

## CROSS-REFERENCE TO RELATED APPLICATIONS

**[0001]** This application claims the benefit of U.S. Provisional Application No. 61/970,247, filed March 25, 2014 and U.S. Provisional Application No. 62/019,007, filed June 30, 2014.

## BACKGROUND OF THE INVENTION

**[0002]** Shock is a life-threatening condition that can result from trauma, severe blood loss, heart attacks, cardiovascular dysfunction, ischemia, sepsis, and burns. Major classes of shock include but are not limited to cardiogenic shock, hypovolemic shock, hemorrhagic shock, anaphylactic shock, neurogenic shock, and septic (or endotoxic) shock. Shock can lead to multi-organ failure (also known as multi-organ dysfunction syndrome) if immediate medical treatment is not received. Under the conditions of shock, the intestinal barrier and walls become compromised and the digestive enzymes that are normally contained within the intestine permeate through the intestinal walls and enter the bloodstream, leading to a condition known as autodigestion, in which the body's digestive enzymes begin to digest its own tissues. Autodigestion is hypothesized to be a mechanism for inflammation and multi-organ failure resulting from shock.

**[0003]** Frank A. Delano et al., "Pancreatic Digestive Enzyme Blockade in the Small Intestine Prevents Insulin Resistance in Hemorrhagic Shock", SHOCK, US, (20140101), vol. 41, no. 1, pages 55 - 61, describes that hemorrhagic shock is associated with metabolic defects, including hyperglycemia and insulin resistance, but the mechanisms are unknown. Delano *et al.*, attempts to determine the degree to which blockade of digestive enzymes affects insulin resistance in shock. The results disclosed suggest that in hemorrhagic shock elevated microvascular extracellular digestive enzyme activity causes insulin receptor dysfunction, hyperglycemia, and reduced ability to regulate blood glucose values.

## SUMMARY OF THE INVENTION

**[0004]** Despite the severity of shock, autodigestion, multi-organ failure, ischemia, and hypoperfusion, few therapies are available. Most efforts have focused on the modulation of individual inflammatory mediators of shock, e.g., cytokines, nitric oxide, and endotoxin, to mitigate the effects of shock. However, therapies that target particular inflammatory mediators have proven largely ineffective due to the multifaceted nature of the mediators. Thus, a need exists for therapeutics to treat shock, autodigestion, multi-organ failure, ischemia, and hypoperfusion, particularly therapeutics that preserve or help reestablish the integrity of the intestinal wall.

**[0005]** Disclosed herein is an aqueous composition comprising about 6.8 grams to about 8.3 grams of tranexamic acid; about 29.3 grams to about 35.8 grams of polyethylene glycol; about 25 grams to about 31 grams of glucose; and one or more electrolytes, wherein the aqueous composition is formulated in an amount of:

1. (i) about 630 mL to about 770 mL; or
2. (ii) about 700 mL;

wherein the term "about" means  $\pm 10\%$  of each numerical value.

**[0006]** Also disclosed herein are compositions for use in the treatment of shock, autodigestion, multi-organ failure, intestinal ischemia, and/or hypoperfusion.

**[0007]** Also disclosed, is a composition described herein, for use in preserving the structural integrity of the gastrointestinal tract under ischemic or hemorrhagic conditions.

**[0008]** Also disclosed, is a kit comprising:

1. (a) a first container which comprises tranexamic acid; polyethylene glycol; and one or more electrolytes;
2. (b) a second container which comprises glucose; and
3. (c) instructions to combine the first container and the second container to form an aqueous composition described herein.

**[0009]** In some embodiments, the PEG is PEG 3350. In certain embodiments, compositions disclosed herein comprise a non-colonic cleansing amount of PEG 3350. In some embodiments, compositions disclosed herein comprise about 7.8 g of tranexamic acid, about 50.3 g of PEG 3350, about 40 g of glucose, about 5.7 g of sodium sulfate, about 1.7 g of sodium bicarbonate, about 1.5 g of sodium chloride, and about 0.7 g of potassium chloride. In some embodiments, compositions disclosed herein comprise about 7.8 g of tranexamic acid and about 40 g of glucose. The compositions disclosed herein are formulated as aqueous solutions. In certain specific embodiments, the volume of the aqueous solution is 1000 mL. In some embodiments, compositions disclosed herein comprise about 7.5 g of tranexamic acid, about 32.5 g of PEG 3350, about 28 g of glucose, about 4.0 g of sodium sulfate, about 1.2 g of sodium bicarbonate, about 1.0 g of sodium chloride, and about 0.5 g of potassium chloride. In some embodiments, compositions disclosed herein comprise about 7.5 g of tranexamic acid and about 28 g of glucose. The compositions disclosed herein are formulated as aqueous solutions. In certain specific embodiments, the volume of the aqueous solution is 700 mL.

**[0010]** Also disclosed, compositions disclosed herein are administered for the treatment of shock, autodigestion, multi-organ failure, intestinal ischemia, or hypoperfusion. In certain specific embodiments of the present disclosure, compositions disclosed herein are

administered for the treatment of cardiogenic shock, hemorrhagic shock, or septic shock. Also disclosed, compositions disclosed herein are administered for the treatment of septic shock associated with or caused by sepsis. Also disclosed, compositions disclosed herein are administered for the treatment of cardiogenic shock associated with or caused by cardiovascular surgery, myocardial infarction, arrhythmia, or mechanical complications. Also disclosed, compositions disclosed herein are administered for the treatment of hemorrhagic shock associated with or caused by trauma. Also disclosed, compositions disclosed herein are administered for the treatment of shock associated with or caused by a hemorrhagic virus. In some embodiments, the hemorrhagic virus is an Ebola virus. In some embodiments, compositions disclosed herein are administered orally, or via a nasogastric, orogastric, nasojejunal, orojejunal, nasoduodenal, or percutaneous endoscopic gastrostomy tube or catheter.

**[0011]** In some embodiments, disclosed herein is a kit comprising: tranexamic acid, PEG, and one or more electrolytes are in a first container, and glucose in a second container. In some embodiments, a kit comprises instructions to reconstitute the components with water to provide an aqueous formulation according to the claims. In some embodiments, a kit comprises a first container comprising about 7.8 g of tranexamic acid, about 50.3 g of PEG 3350, about 5.7 g of sodium sulfate, about 1.7 g of sodium bicarbonate, about 1.5 g of sodium chloride, and about 0.7 g of potassium chloride, and a second container comprising about 40 g of glucose. In some embodiments, a kit comprises a first container comprising about 7.8 g of tranexamic acid, about 50.3 g of PEG 3350, about 5.7 g of sodium sulfate, about 1.7 g of sodium bicarbonate, about 1.5 g of sodium chloride, and about 0.7 g of potassium chloride, a second container comprising about 40 g of glucose, and instructions to reconstitute the tranexamic acid, PEG, glucose, and one or more electrolytes with water to 1000 mL. In some embodiments, a kit comprises a first container comprising about 7.5 g of tranexamic acid, about 32.5 g of PEG 3350, about 4.0 g of sodium sulfate, about 1.2 g of sodium bicarbonate, about 1.0 g of sodium chloride, and about 0.5 g of potassium chloride, and a second container comprising about 28 g of glucose. In some embodiments, a kit comprises a first container comprising about 7.5 g of tranexamic acid, about 32.5 g of PEG 3350, about 4.0 g of sodium sulfate, about 1.2 g of sodium bicarbonate, about 1.0 g of sodium chloride, and about 0.5 g of potassium chloride, a second container comprising about 28 g of glucose, and instructions to reconstitute the tranexamic acid, PEG, glucose, and one or more electrolytes with water to 700 mL. In some embodiments, a kit comprises instructions to administer the combined components orally or via a nasogastric, orogastric, nasojejunal, orojejunal, nasoduodenal, or percutaneous endoscopic gastrostomy tube or catheter.

#### BRIEF DESCRIPTION OF THE DRAWINGS

**[0012]** The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying

drawings of which:

**Figure 1** shows a representative cross section of the small intestine from a rat treated with an enteral formulation and superior mesentery artery occlusion (SMAO). Healthy villi are marked with n and damaged villi are marked with d.

**Figures 2A and 2B** show the cross sections of the small intestines of rats following treatment with Representative Formulation 1 and Comparative Formulation 1, respectively. **Figure 2A** shows that rat intestinal villi appear healthy and structurally intact and that the entire length of the villi is visible and completely covered in goblet cells, following administration of Representative Formulation 1 and shock induction according to Example 2. **Figure 2B** shows that rat intestinal villi are structurally damaged, with missing villi tips and atypical goblet cell staining, following administration of Comparative Formulation 1 and shock induction according to Example 2.

**Figure 3** illustrates the percentage of villi that were structurally intact with intact epithelial lining in all rats treated in Example 2. Representative Formulation 1 preserved on average 92.6% of villi, while Comparative Formulation 1 preserved on average 52.8% of the villi. Data are averages  $\pm$  SEM; n = 4 rats in each group; \* $=p<0.01$  compared to respective treated group, ANOVA.

**Figures 4A and 4B** show the cross section of the small intestine from a rat treated with Representative Formulation 2 and Comparative Formulation 2, respectively. **Figure 4A** shows that villi appear healthy and structurally intact and that the entire length of the villi is visible and completely covered in goblet cells, following administration of Representative Formulation 2 and shock induction according to Example 3. **Figure 4B** shows that rat villi are structurally damaged, with missing villi tips and atypical goblet cell staining, following administration of Comparative Formulation 2 and shock induction according to Example 3.

**Figure 5** illustrates the percentage of villi that were structurally intact with intact epithelial lining in all rats treated in Example 3. Representative Formulation 2 preserved on average 83.4% of villi, while Comparative Formulation 2 preserved on average 51.3% of the villi. Data are averages  $\pm$  SEM; n = 4 rats in each group; \* $=p<0.01$  compared to respective treated group, ANOVA.

**Figures 6A and 6B** show the cross section of the small intestine from a rat treated with Representative Formulation 3 and Comparative Formulation 3, respectively. **Figure 6A** shows that villi appear healthy and structurally intact and that the entire length of the villi is visible and completely covered in goblet cells, following administration of Representative Formulation 3 and hemorrhagic shock induction according to Example 4. **Figure 6B** shows that rat villi are structurally damaged following administration of Comparative Formulation 3 and hemorrhagic shock induction according to Example 4.

**Figure 7** illustrates the percentage of villi that were structurally intact with intact epithelial lining in all rats treated in Example 4. Representative Formulation 3 preserved on average 88.8% of villi, while Comparative Formulation 3 preserved on average 64.1% of the villi. Data are

averages  $\pm$  SEM; n = 4 rats in each group; \* $=p<0.01$  compared to respective treated group, ANOVA.

## DETAILED DESCRIPTION OF THE INVENTION

**[0013]** Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of skill in the art to which the inventions described herein belong.

### Definition of Terms

**[0014]** When the term "about" is present before a numerical value herein, it means  $\pm$  10% of the numerical value. For example, as used herein, the term "about 10 g" means an amount from 9 g to 11 g.

**[0015]** As used herein, the terms "comprising," "including," "such as," and "for example" (or "e.g.") are used in their open, non-limiting sense.

**[0016]** The term "treat" and its grammatical variants (e.g., "to treat," "treating," and "treatment") refer to administration of an active pharmaceutical ingredient to a patient with the purpose of ameliorating or reducing the incidence of one or more symptoms of a condition or disease state in the patient. In some embodiments, such symptoms are chronic or acute, and such amelioration are partial or complete for some instances. In the present context, treatment entails administering a pharmaceutical composition described herein to a patient via a route of administration disclosed herein.

**[0017]** As used herein, "PEG" refers to a polyethylene glycol polymer. When "PEG" is used in combination with a numerical value, the numerical value defines the average molecular weight of the polyethylene glycol polymer. For an example PEG 3350 refers to a polyethylene glycol polymer that has an average molecular weight of 3,350 Da.

**[0018]** As used herein, the term "non-colonic cleansing amount" refers to an amount of a substance that does not cause significant or substantially all removal of feces and toxins from the colon and intestinal tract when administered to the gastrointestinal tract.

**[0019]** As used herein, the terms "electrolyte" and "electrolytes" are used to describe any substances that ionize when dissolved in an ionizing solvent, such as water. Electrolytes include, but are not limited to, soluble salts, acids, or bases.

**[0020]** As used herein, the term "wt%" refers to the weight percent of a given component in a

composition. For example, as used herein, an aqueous solution comprising 4 wt% glucose refers to an aqueous solution that comprises 4 grams of glucose per 100 grams of the solution.

## **Compositions**

**[0021]** Disclosed herein are compositions for use in the treatment of shock, autodigestion, multi-organ failure, intestinal ischemia, or hypoperfusion. The compositions disclosed herein comprise tranexamic acid.

**[0022]** In some embodiments, the compositions disclosed herein comprise about 6.8 g, about 6.9 g, about 7.0 g, about 7.1 g, about 7.2 g, about 7.3 g, about 7.4 g, about 7.5 g, about 7.6 g, about 7.7 g, about 7.8 g, about 7.9 g, about 8.0 g, about 8.1 g, about 8.2 or about 8.3 g of tranexamic acid. In a specific embodiment, compositions disclosed herein comprise about 7.5 g of tranexamic acid. In some embodiments, compositions disclosed herein comprise about 6.8 g to about 8.3 g of tranexamic acid.

**[0023]** In some embodiments, compositions disclosed herein comprise a non-colonic cleansing amount of PEG. In certain specific embodiments, compositions disclosed herein comprise a non-colonic cleansing amount of PEG 2000, PEG 3000, PEG 3350, or PEG 4000. In a specific embodiment, compositions disclosed herein comprise a non-colonic cleansing amount of PEG 3350. In a specific embodiment, a non-colonic cleansing amount of PEG, e.g., PEG 3350 is about 50.3 g.

**[0024]** In some embodiments, a non-colonic cleansing amount of PEG, e.g., PEG 3350, is about 29.3 g, about 29.4 g, about 29.5 g, about 29.6 g, about 29.7 g, about 29.8 g, about 29.9 g, about 30.0 g, about 30.1 g, about 30.2 g, about 30.3 g, about 30.4 g, about 30.5 g, about 30.6 g, about 30.7 g, about 30.8 g, about 30.9 g, about 31.0 g, about 31.1 g, about 31.2 g, about 31.3 g, about 31.4 g, about 31.5 g, about 31.6 g, about 31.7 g, about 31.8 g, about 31.9 g, about 32.0 g, about 32.1 g, about 32.2 g, about 32.3 g, about 32.4 g, about 32.5 g, about 32.6 g, about 32.7 g, about 32.8 g, about 32.9 g, about 33.0 g, about 33.1 g, about 33.2 g, about 33.3 g, about 33.4 g, about 33.5 g, about 33.6 g, about 33.7 g, about 33.8 g, about 33.9 g, about 34.0 g, about 34.1 g, about 34.2 g, about 34.3 g, about 34.4 g, about 34.5 g, about 34.6 g, about 34.7 g, about 34.8 g, about 34.9 g, about 35.0 g, about 35.1 g, about 35.2 g, about 35.3 g, about 35.4 g, about 35.5 g, about 35.6 g, about 35.7 g, or about 35.8 g. In a specific embodiment, a non-colonic cleansing amount of PEG, e.g., PEG 3350 is about 32.5 g. In some embodiments, a non-colonic cleansing amount of PEG, e.g., PEG 3350, is about 29.3 g to about 35.8 g.

**[0025]** In some embodiments, compositions disclosed herein are formulated as aqueous solutions comprising about 4.5 wt%, about 4.6 wt%, about 4.7 wt%, about 4.8 wt%, about 4.9 wt%, about 5.0 wt%, about 5.1 wt%, about 5.2 wt%, about 5.3 wt%, about 5.4 wt%, or about 5.5 wt% of PEG. In certain embodiments, compositions disclosed herein are formulated as aqueous solutions comprising about 4.5 wt%, about 4.6 wt%, about 4.7 wt%, about 4.8 wt%,

about 4.9 wt%, about 5.0 wt%, about 5.1 wt%, about 5.2 wt%, about 5.3 wt%, about 5.4 wt%, or about 5.5 wt% of PEG 3350. In a specific embodiment, compositions disclosed herein are formulated as aqueous solutions comprising about 5.0 wt% of PEG. In certain embodiments, compositions disclosed herein are formulated as aqueous solutions comprising about 4.5 wt% to about 5.5 wt% of PEG. In a specific embodiment, compositions disclosed herein are formulated as aqueous solutions comprising about 5.0 wt% of PEG 3350. In certain embodiments, compositions disclosed herein are formulated as aqueous solutions comprising about 4.5 wt% to about 5.5 wt% of PEG 3350.

**[0026]** In some embodiments, compositions disclosed herein are formulated as aqueous solutions comprising about 4.2 wt%, about 4.3 wt%, about 4.4 wt%, about 4.5 wt%, about 4.6 wt%, about 4.7 wt%, about 4.8 wt%, about 4.9 wt%, about 5.0 wt%, or about 5.1 wt% of PEG. In some embodiments, compositions disclosed herein are formulated as aqueous solutions comprising about 4.2 wt%, about 4.3 wt%, about 4.4 wt%, about 4.5 wt%, about 4.6 wt%, about 4.7 wt%, about 4.8 wt%, about 4.9 wt%, about 5.0 wt%, or about 5.1 wt% of PEG 3350. In a specific embodiment, compositions disclosed herein are formulated as aqueous solutions comprising about 4.6 wt% of PEG. In certain embodiments, compositions disclosed herein are formulated as aqueous solutions comprising about 4.2 wt% to about 5.1 wt% of PEG. In a specific embodiment, compositions disclosed herein are formulated as aqueous solutions comprising about 4.6 wt% of PEG 3350. In certain embodiments, compositions disclosed herein are formulated as aqueous solutions comprising about 4.2 wt% to about 5.1 wt% of PEG 3350.

**[0027]** The compositions disclosed herein comprise glucose. In some embodiments, compositions disclosed herein comprise about 25 g, about 26 g, about 27 g, about 28 g, about 29 g, about 30 g, about 31 g, or about 40 g of glucose. In a specific embodiment, compositions disclosed herein comprise about 40 g of glucose. In a specific embodiment, compositions disclosed herein comprise about 30 g of glucose.

**[0028]** In some embodiments, compositions disclosed herein comprise about 25 g, about 26 g, about 27 g, about 28 g, about 29 g, about 30 g, or about 31 g of glucose. In a specific embodiment, compositions disclosed herein comprise about 28 g of glucose. In certain embodiments, compositions disclosed herein comprise about 25 g to about 31 g of glucose.

**[0029]** In some embodiments, compositions disclosed herein are formulated as aqueous solutions comprising about 3.3 wt%, about 3.4 wt%, about 3.5 wt%, about 3.6 wt%, about 3.7 wt%, about 3.8 wt%, about 3.9 wt%, about 4.0 wt%, about 4.1 wt%, about 4.2 wt%, about 4.3 wt%, about 4.4 wt%, about 4.5 wt%, about 4.6 wt%, about 4.7 wt%, about 4.8 wt%, or about 4.9 wt% of glucose. In a specific embodiment, compositions disclosed herein are formulated as aqueous solutions comprising about 4 wt% of glucose.

**[0030]** In some embodiments, compositions disclosed herein are formulated as aqueous solutions comprising about 3.6 wt%, about 3.7 wt%, about 3.8 wt%, about 3.9 wt%, about 4.0 wt%, about 4.1 wt%, about 4.2 wt%, about 4.3 wt%, or about 4.4 wt% of glucose. In a specific

embodiment, compositions disclosed herein are formulated as aqueous solutions comprising about 4 wt% of glucose. In certain embodiments, compositions disclosed herein are formulated as aqueous solutions comprising about 3.6 wt% to about 4.4 wt% of glucose.

**[0031]** In some embodiments, compositions disclosed herein comprise one or more electrolytes. In certain embodiments, the one or more electrolytes comprise sodium chloride (NaCl). In some embodiments, compositions disclosed herein comprise about 1.0 g, about 1.1 g, about 1.2 g, about 1.3 g, about 1.4 g, about 1.5 g, about 1.6 g, or about 1.7 g of sodium chloride. In a specific embodiment, compositions disclosed herein comprise about 1.5 g of sodium chloride. In some embodiments, compositions disclosed herein comprise about 1.3 g to about 1.7 g of sodium chloride. In a specific embodiment, compositions disclosed herein comprise about 1.1 g of sodium chloride. In some embodiments, compositions disclosed herein comprise about 1.0 g to about 1.2 g of sodium chloride. In a specific embodiment, compositions disclosed herein comprise about 1.2 g of sodium chloride. In some embodiments, compositions disclosed herein comprise about 1.1 g to about 1.3 g of sodium chloride.

**[0032]** In some embodiments, compositions disclosed herein comprise about 0.9 g, about 1.0 g, or about 1.1 g of sodium chloride. In a specific embodiment, compositions disclosed herein comprise about 1.0 g of sodium chloride. In some embodiments, compositions disclosed herein comprise about 0.9 g to about 1.1 g of sodium chloride.

**[0033]** In some embodiments, compositions disclosed herein are formulated as aqueous solutions comprising about 0.13 wt%, about 0.14 wt%, about 0.15 wt%, about 0.16 wt%, about 0.17 wt% of sodium chloride. In a specific embodiment, compositions disclosed herein are formulated as aqueous solutions comprising about 0.15 wt% of sodium chloride. In some embodiments, compositions disclosed herein are formulated as aqueous solutions comprising about 0.13 wt% to about 0.17 wt% of sodium chloride.

**[0034]** In some embodiments, the one or more electrolytes comprise sodium sulfate (Na<sub>2</sub>SO<sub>4</sub>). In some embodiments, compositions disclosed herein comprise about 3.9 g, about 4.0 g, about 4.1 g, about 4.2 g, about 4.3 g, about 4.4 g, about 4.5 g, about 4.6 g, about 4.7 g, about 4.8 g, about 4.9 g, about 5.0 g, about 5.1 g, about 5.2 g, about 5.3 g, about 5.4 g, about 5.5 g, about 5.6 g, about 5.7 g, about 5.8 g, about 5.9 g, about 6.0 g, about 6.1 g, about 6.2 or about 6.3 g of sodium sulfate. In a specific embodiment, compositions disclosed herein comprise about 5.7 g of sodium sulfate. In some embodiments, compositions disclosed herein comprise about 5.1 g to about 6.3 g of sodium sulfate. In a specific embodiment, compositions disclosed herein comprise about 4.3 g of sodium sulfate. In some embodiments, compositions disclosed herein comprise about 3.9 g to about 4.7 g of sodium sulfate. In a specific embodiment, compositions disclosed herein comprise about 4.6 g of sodium sulfate. In some embodiments, compositions disclosed herein comprise about 4.1 g to about 5.1 g of sodium sulfate.

**[0035]** In some embodiments, compositions disclosed herein comprise about 3.6 g, about 3.7 g, about 3.8 g, about 3.9 g, about 4.0 g, about 4.1 g, about 4.2 g, about 4.3 g, or about 4.4 g of sodium sulfate. In a specific embodiment, compositions disclosed herein comprise about 4.0 g

of sodium sulfate. In some embodiments, compositions disclosed herein comprise about 3.6 g to about 4.4 g of sodium sulfate.

**[0036]** In some embodiments, compositions disclosed herein are formulated as aqueous solutions comprising sodium sulfate. In some embodiments, the compositions disclosed herein are formulated as aqueous solutions comprising about 0.51 wt%, about 0.52 wt%, about 0.53 wt%, about 0.54 wt%, about 0.55 wt%, about 0.56 wt%, about 0.57 wt%, about 0.58 wt%, about 0.59 wt%, about 0.60 wt%, about 0.61 wt%, about 0.62 wt%, or about 0.63 wt% of sodium sulfate. In a specific embodiment, compositions disclosed herein are formulated as aqueous solutions comprising about 0.57 wt% of sodium sulfate. In some embodiments, compositions disclosed herein are formulated as aqueous solutions comprising about 0.51 wt% to about 0.63 wt% of sodium sulfate.

**[0037]** In some embodiments, the one or more electrolytes comprise sodium bicarbonate ( $\text{NaHCO}_3$ ). In some embodiments, compositions disclosed herein comprise about 1.2 g, about 1.3 g, about 1.4 g, about 1.5 g, about 1.6 g, about 1.7 g, about 1.8 g, or about 1.9 g of sodium bicarbonate. In a specific embodiment, compositions disclosed herein comprise about 1.7 g of sodium bicarbonate. In some embodiments, compositions disclosed herein comprise about 1.5 g to about 1.9 g of sodium bicarbonate. In a specific embodiment, compositions disclosed herein comprise about 1.3 g of sodium bicarbonate. In some embodiments, compositions disclosed herein comprise about 1.2 g to about 1.4 g of sodium bicarbonate. In a specific embodiment, compositions disclosed herein comprise about 1.4 g of sodium bicarbonate. In some embodiments, compositions disclosed herein comprise about 1.3 g to about 1.5 g of sodium bicarbonate.

**[0038]** In some embodiments, compositions disclosed herein comprise about 1.1 g, about 1.2 g, or about 1.3 g of sodium bicarbonate. In a specific embodiment, compositions disclosed herein comprise about 1.2 g of sodium bicarbonate. In some embodiments, compositions disclosed herein comprise about 1.1 g to about 1.3 g of sodium bicarbonate.

**[0039]** In some embodiments, compositions disclosed herein are formulated as aqueous solutions comprising about 0.15 wt%, about 0.16 wt%, about 0.17 wt%, about 0.18 wt%, or about 0.19 wt% of sodium bicarbonate. In a specific embodiment, compositions disclosed herein are formulated as aqueous solutions comprising about 0.17 wt% of sodium bicarbonate. In some embodiments, compositions disclosed herein are formulated as aqueous solutions comprising about 0.15 wt% to about 0.19 wt% of sodium bicarbonate.

**[0040]** In some embodiments, compositions disclosed herein are formulated as aqueous solutions comprising about 0.16 wt%, about 0.17 wt%, about 0.18 wt%, or about 0.19 wt% of sodium bicarbonate. In a specific embodiment, compositions disclosed herein are formulated as aqueous solutions comprising about 0.17 wt% of sodium bicarbonate. In some embodiments, compositions disclosed herein are formulated as aqueous solutions comprising about 0.16 wt% to about 0.19 wt% of sodium bicarbonate.

**[0041]** In some embodiments, the one or more electrolytes comprise potassium chloride (KC1). In some embodiments, compositions disclosed herein comprise about 0.4 g, about 0.5 g, about 0.6 g, about 0.7 g or about 0.8 g of potassium chloride. In a specific embodiment, compositions disclosed herein comprise about 0.7 g of potassium chloride. In some embodiments, compositions disclosed herein comprise about 0.6 g to about 0.8 g of potassium chloride. In a specific embodiment, compositions disclosed herein comprise about 0.5 g of potassium chloride. In some embodiments, compositions disclosed herein comprise about 0.4 g to about 0.6 g of potassium chloride. In a specific embodiment, compositions disclosed herein comprise about 0.6 g of potassium chloride. In some embodiments, compositions disclosed herein comprise about 0.5 g to about 0.7 g of potassium chloride.

**[0042]** In some embodiments, compositions disclosed herein comprise about 0.4 g, about 0.5 g, or about 0.6 g of potassium chloride. In a specific embodiment, compositions disclosed herein comprise about 0.5 g of potassium chloride. In some embodiments, compositions disclosed herein comprise about 0.4 g to about 0.6 g of potassium chloride.

**[0043]** In some embodiments, compositions disclosed herein are formulated as aqueous solutions comprising about 0.06 wt%, about 0.07 wt%, or about 0.08 wt% of potassium chloride. In a specific embodiment, compositions disclosed herein are formulated as aqueous solutions comprising about 0.07 wt% of potassium chloride. In some embodiments, compositions disclosed herein are formulated as aqueous solutions comprising about 0.06 wt% to about 0.08 wt% of potassium chloride.

**[0044]** In some embodiments, compositions disclosed herein are formulated as aqueous solutions comprising about 0.06 wt%, about 0.07 wt%, about 0.08 wt%, or about 0.09% wt of potassium chloride. In a specific embodiment, compositions disclosed herein are formulated as aqueous solutions comprising about 0.07 wt% of potassium chloride. In some embodiments, compositions disclosed herein are formulated as aqueous solutions comprising about 0.06 wt% to about 0.09 wt% of potassium chloride.

**[0045]** In some aspects of the disclosure the compositions disclosed herein are formulated into any suitable dosage form, including but not limited to solutions, dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, liquids, gels, syrups, elixirs, lyophilized formulations, powders, or multiparticulate formulations. Such formulations are optionally manufactured in a conventional manner, such as, by way of example only, conventional mixing, dissolving, emulsifying, and the like. In some embodiments, compositions disclosed herein are formulated as a powder for reconstitution. According to the invention, the compositions disclosed herein are formulated as an aqueous solution.

**[0046]** The disclosed herein are formulated as, an aqueous solution. In some embodiments, compositions disclosed herein are formulated as a an aqueous solution, having a volume of about 630 mL, about 640 mL, about 650 mL, about 660 mL, about 670 mL, about 680 mL, about 690 mL, about 700 mL, about 710 mL, about 720 mL, about 730 mL, about 740 mL, about 750 mL, about 760 mL, about 770 mL, or about 1000 mL.

**[0047]** In some embodiments, compositions disclosed herein are formulated as an aqueous solution, having a volume of about 630 mL, about 640 mL, about 650 mL, about 660 mL, about 670 mL, about 680 mL, about 690 mL, about 700 mL, about 710 mL, about 720 mL, about 730 mL, about 740 mL, about 750 mL, about 760 mL, or about 770 mL. In a specific embodiment, compositions disclosed herein are formulated as a solution, e.g., an aqueous solution, having a volume of about 700 mL. In some embodiments, compositions disclosed herein are formulated as an aqueous solution, having a volume of about 630 mL to about 770 mL.

**[0048]** In certain specific embodiments, compositions disclosed herein comprise about 7.8 g of tranexamic acid and about 25 g, about 26 g, about 27 g, about 28 g, about 29 g, about 30 g, about 31 g, or about 40 g of glucose. In a specific embodiment, compositions disclosed herein comprise about 7.8 g of tranexamic acid and about 40 g of glucose.

**[0049]** In some embodiments, compositions disclosed herein comprise about 6.8 g to about 8.3 g of tranexamic acid and about 25 g to about 31 g of glucose. In certain specific embodiments, compositions disclosed herein comprise about 7.5 g of tranexamic acid and about 25 g, about 26 g, about 27 g, about 28 g, about 29 g, about 30 g, or about 31 g of glucose. In a specific embodiment, compositions disclosed herein comprise about 7.5 g of tranexamic acid and about 28 g of glucose.

**[0050]** In certain specific embodiments, compositions disclosed herein comprise about 7.8 g of tranexamic acid and about 33.9 g, about 34.0 g, about 34.1 g, about 34.2 g, about 34.3 g, about 34.4 g, about 34.5 g, about 34.6 g, about 34.7 g, about 34.8 g, about 34.9 g, about 35.0 g, about 35.1 g, about 35.2 g, about 35.3 g, about 35.4 g, about 35.5 g, about 35.6 g, about 35.7 g, about 35.8 g, or about 50.3 g of PEG 3350.

**[0051]** In some embodiments, compositions disclosed herein comprise about 6.8 g to about 8.3 g of tranexamic acid and about 29.3 g to about 35.8 g of PEG 3350. In certain specific embodiments, compositions disclosed herein comprise about 7.5 g of tranexamic acid and about 29.3 g, about 29.4 g, about 29.5 g, about 29.6 g, about 29.7 g, about 29.8 g, about 29.9 g, about 30.0 g, about 30.1 g, about 30.2 g, about 30.3 g, about 30.4 g, about 30.5 g, about 30.6 g, about 30.7 g, about 30.8 g, about 30.9 g, about 31.0 g, about 31.1 g, about 31.2 g, about 31.3 g, about 31.4 g, about 31.5 g, about 31.6 g, about 31.7 g, about 31.8 g, about 31.9 g, about 32.0 g, about 32.1 g, about 32.2 g, about 32.3 g, about 32.4 g, about 32.5 g, about 32.6 g, about 32.7 g, about 32.8 g, about 32.9 g, about 33.0 g, about 33.1 g, about 33.2 g, about 33.3 g, about 33.4 g, about 33.5 g, about 33.6 g, about 33.7 g, about 33.8 g, about 33.9 g, about 34.0 g, about 34.1 g, about 34.2 g, about 34.3 g, about 34.4 g, about 34.5 g, about 34.6 g, about 34.7 g, about 34.8 g, about 34.9 g, about 35.0 g, about 35.1 g, about 35.2 g, about 35.3 g, about 35.4 g, about 35.5 g, about 35.6 g, about 35.7 g, or about 35.8 g of PEG 3350. In a specific embodiment, compositions disclosed herein comprise about 7.5 g of tranexamic acid and about 32.5 g of PEG 3350.

**[0052]** In a specific embodiment, compositions disclosed herein are formulated as aqueous

solutions comprising about 7.8 g of tranexamic acid, about 5.0 wt% of PEG 3350, about 4 wt% of glucose, about 0.57 wt% of sodium sulfate, about 0.17 wt% of sodium bicarbonate, about 0.15 wt% of sodium chloride, and about 0.07 wt% of potassium chloride.

**[0053]** In some embodiments, compositions disclosed herein are formulated as aqueous solutions comprising about 6.8 g to about 8.3 g of tranexamic acid, about 4.2 wt% to about 5.1 wt% of PEG 3350, about 3.6 wt% to about 4.4 wt% of glucose, about 0.51 wt% to about 0.63 wt% of sodium sulfate, about 0.16 wt% to about 0.19 wt% of sodium bicarbonate, about 0.13 wt% to about 0.17 wt% of sodium chloride, and about 0.06 wt% to about 0.09 wt% of potassium chloride. In a specific embodiment, compositions disclosed herein are formulated as aqueous solutions comprising about 7.5 g of tranexamic acid, about 4.6 wt% of PEG 3350, about 4 wt% of glucose, about 0.57 wt% of sodium sulfate, about 0.17 wt% of sodium bicarbonate, about 0.15 wt% of sodium chloride, and about 0.07 wt% of potassium chloride.

**[0054]** In some embodiments, the compositions disclosed herein are formulated with one or more inactive ingredients or pharmaceutical excipients that provide suitable properties of the formulation. Such inactive ingredients include but are not limited to antioxidants, carriers, viscosity modulating agents, diluents, flavoring agents, preservatives, solubilizers, stabilizers, suspending agents, and surfactants. Any suitable amounts of such inactive ingredients are determined according to the particular properties desired.

**[0055]** Compositions for Use in Methods of Treatment The references to methods of treatment in this paragraph are to be interpreted as references to the compounds, pharmaceutical compositions and medicaments of the present invention for use in a method for treatment of the human (or animal) body by therapy.

**[0056]** Also disclosed, the compositions disclosed herein are administered for the treatment of shock, autodigestion, multi-organ failure, ischemia, or hypoperfusion. In certain specific embodiments or the present disclosure, compositions disclosed herein are administered for the treatment of cardiogenic shock, hemorrhagic shock, or septic shock. In some embodiments, ischemia is intestinal ischemia. Also disclosed, compositions disclosed herein are administered for the treatment of septic shock associated with or caused by sepsis. Also disclosed, compositions disclosed herein are administered for the treatment of cardiovascular shock associated with or caused by cardiovascular surgery, myocardial infarction, arrhythmia, or mechanical complications. In some embodiments, a mechanical complication is a cardiovascular mechanical complication. Also disclosed, compositions disclosed herein are administered for the treatment of cardiovascular shock associated with or caused by myocardial infarction or mechanical complications. Also disclosed, compositions disclosed herein are administered for the treatment of hemorrhagic or hypovolemic shock associated with or caused by trauma. Also disclosed, compositions disclosed herein may be administered for the treatment of hemorrhagic or hypovolemic shock associated with or caused by Ebola Virus Disease or other hemorrhagic virus. Also disclosed, compositions disclosed herein are administered for the treatment of intestinal ischemia or hypoperfusion that result in shock. Also disclosed, compositions disclosed herein may be administered for the treatment of

Inflammatory Bowel Disease or Crohn's Disease, or complications arising from Inflammatory Bowel Disease or Crohn's Disease. Also disclosed, compositions disclosed herein may be administered for the treatment of *Clostridium difficile* colitis, or complications that arise from *Clostridium difficile* colitis.

**[0057]** In some embodiments, the compositions disclosed herein are administered to a subject, e.g., a human, by multiple administration routes, either alone or concurrently, including but not limited to oral, nasogastric, orogastric, nasojejunal, orojejunal, nasoduodenal, or percutaneous endoscopic gastrostomy administration or other enteral routes. In some embodiments, compositions disclosed herein are administered directly to the gastrointestinal tract. In some embodiments, compositions disclosed herein are administered to the stomach. In some embodiments, compositions disclosed herein are administered to the small intestine. In certain embodiments, compositions disclosed herein are administered via a nasogastric, orogastric, nasojejunal, orojejunal, nasoduodenal, or percutaneous endoscopic gastrostomy tube or catheter. In some embodiments, compositions disclosed herein are delivered orally or by direct injection. In some embodiments of the methods disclosed herein, compositions are administered by a single route of administration. In some embodiments of the methods disclosed herein, compositions are administered by multiple routes of administration.

### **Kits**

**[0058]** In some embodiments, the components of the compositions disclosed herein are provided in kits wherein one or more of the components are contained in separate packages or containers along with instructions to combine the components in a single composition. In some embodiments, a kit comprises instructions to reconstitute the components in a liquid carrier, such as water, to produce a liquid, e.g., aqueous, formulation comprising the components. In some instances, the components of the compositions disclosed herein are provided in a single package or container with instructions to reconstitute them in a liquid carrier, such as water, to produce a liquid, e.g., aqueous, formulation. In some embodiments, the components of the compositions disclosed herein are provided in kits wherein one or more of the components are contained in separate packages or containers, and wherein a liquid carrier, such as water, is also provided in a separate package or container in the kit, along with instructions to combine the components and liquid carrier in a single composition to produce a liquid, e.g., aqueous, formulation. In some embodiments, a kit comprises instructions to administer a composition or formulation disclosed herein orally or via a nasogastric, orogastric, nasojejunal, orojejunal, nasoduodenal, or percutaneous endoscopic gastrostomy tube or catheter to a subject, e.g., a human, to treat shock, autodigestion, multi-organ failure, ischemia, or hypoperfusion.

**[0059]** In certain specific embodiments, a kit comprises tranexamic acid and glucose packaged in separate containers. In some embodiments, a kit comprises tranexamic acid, polyethylene glycol, and one or more electrolytes in a first container and glucose in a second container. In some instances, the containers are made of any suitable packaging material and in any form suitable for the distribution of pharmaceutical products.

**[0060]** In some embodiments, a kit comprises tranexamic acid, PEG, and one or more electrolytes are in a first container, and glucose in a second container. In some embodiments, a kit comprises instructions to combine the tranexamic acid, PEG, one or more electrolytes, and glucose, and reconstitute them in water. In some embodiments, a kit comprises a first container comprising about 7.8 g of tranexamic acid, about 50.3 g of PEG 3350, about 5.7 g of sodium sulfate, about 1.7 g of sodium bicarbonate, about 1.5 g of sodium chloride, and about 0.7 g of potassium chloride, and a second container comprising about 40 g of glucose. In some embodiments, a kit comprises a first container comprising about 7.8 g of tranexamic acid, about 50.3 g of PEG 3350, about 5.7 g of sodium sulfate, about 1.7 g of sodium bicarbonate, about 1.5 g of sodium chloride, and about 0.7 g of potassium chloride, a second container comprising about 40 g of glucose, and instructions to reconstitute the tranexamic acid, PEG, glucose, and one or more electrolytes with water to 1000 mL. In some embodiments, a kit comprises a first container comprising about 7.5 g of tranexamic acid, about 32.5 g of PEG 3350, about 4.0 g of sodium sulfate, about 1.2 g of sodium bicarbonate, about 1.0 g of sodium chloride, and about 0.5 g of potassium chloride, and a second container comprising about 28 g of glucose. In some embodiments, a kit comprises a first container comprising about 7.5 g of tranexamic acid, about 32.5 g of PEG 3350, about 4.0 g of sodium sulfate, about 1.2 g of sodium bicarbonate, about 1.0 g of sodium chloride, and about 0.5 g of potassium chloride, a second container comprising about 28 g of glucose, and instructions to reconstitute the tranexamic acid, PEG, glucose, and one or more electrolytes with water to 700 mL. In some embodiments, a kit comprises instructions to administer the combined components orally or via a nasogastric, orogastric, nasojejunal, orojejunal, nasoduodenal, or percutaneous endoscopic gastrostomy tube or catheter.

### Testing

**[0061]** In some embodiments, the compositions disclosed herein are tested in animal models that are indicative of efficacy in the treatment of shock, autodigestion, multi-organ failure, trauma, sepsis, and ischemia. Such animal models include but are not limited to the minipig hemorrhagic shock model, rat hemorrhagic shock, rat superior mesentery artery occlusion shock, rodent peritonitis shock by placement of cecal material into the peritoneum, rodent endotoxin shock models, and rodent models of bacterial sepsis established through a *Pseudomonas* infection.

### EXAMPLES

**[0062]** Compositions outside the scope of the claims are not part of the invention.

#### *Example 1: Exemplary Compositions*

**[0063]** Exemplary compositions are described in **Tables 1** and **2**. In some embodiments, the compositions according to the instant disclosure are prepared as a dry powder formulation and reconstituted as shown. **Table 1** shows a composition for reconstitution in water to 1000 mL. **Table 2** shows a composition for reconstitution in water to 700 mL. In some instances, upon reconstitution, compositions are administered to a patient in need thereof, e.g., orally or directly to the gastrointestinal tract via a nasogastric, orogastric, nasojejunal, orojejunal, nasoduodenal, or percutaneous endoscopic gastrostomy tube or catheter.

**Table 1**

Component	Amount (g) for 1000 mL solution	Concentration (wt%) in 1000 mL aqueous solution
Tranexamic acid	7.8 ± 10%	0.78 ± 10%
PEG 3350	50.3 ± 10%	5.03 ± 10%
Sodium Sulfate	5.7 ± 10%	0.57 ± 10%
Sodium Bicarbonate	1.7 ± 10%	0.17 ± 10%
Sodium Chloride	1.5 ± 10%	0.15 ± 10%
Potassium Chloride	0.7 ± 10%	0.07 ± 10%
Glucose	40 ± 10%	4.0 ± 10%

**Table 2**

Component	Amount (g) for 700 mL solution	Concentration (wt%) in 700 mL aqueous solution
Tranexamic acid	7.5 ± 10%	1.1 ± 10%
PEG 3350	32.5 ± 10%	4.6 ± 10%
Sodium Sulfate	4.0 ± 10%	0.57 ± 10%
Sodium Bicarbonate	1.2 ± 10%	0.17 ± 10%
Sodium Chloride	1.0 ± 10%	0.15 ± 10%
Potassium Chloride	0.5 ± 10%	0.07 ± 10%
Glucose	28 ± 10%	4.0 ± 10%

**Example 2: Superior Mesentery Artery Occlusion (SMAO) Shock Studies with Formulations Administered via Oral Gavage**

**[0064]** The SMAO model was used to assess the ability of a representative composition

comprising PEG 3350 (Representative Formulation 1) and a comparative composition without PEG 3350 (Comparative Formulation 1) to preserve the structural integrity of the gastrointestinal tract under ischemic conditions when administered by oral gavage.

***Formulation Preparation***

**[0065]** The materials used to prepare the formulations and their sources are shown in **Table 3**. All materials used were USP grade. As shown in **Table 3**, Representative Formulation 1 comprises tranexamic acid, electrolytes, PEG 3350, and glucose, and Comparative Formulation 1 comprises tranexamic acid, electrolytes, and glucose.

**Table 3**

Component	Representative Formulation 1	Comparative Formulation 1	Source
Tranexamic Acid	0.043 g	0.043 g	Daiichi Sankyo
PEG 3350	0.287 g	0.0 g	OTC clinical grade Miralax
Sodium Sulfate (Anhydrous)	0.033 g	0.033 g	Sigma-Aldrich
Sodium Bicarbonate	0.010 g	0.010 g	Sigma-Aldrich
Sodium Chloride	0.009 g	0.009 g	Sigma-Aldrich
Potassium Chloride	0.004 g	0.004 g	Sigma-Aldrich
Glucose	0.229 g	0.229 g	Sigma-Aldrich
Water	3.629 g	3.629 g	Sterile water for injection
Total Solution	4.000 mL	4.000 mL	

***Rats and Diet***

**[0066]** Male WISTAR rats with a weight of 360-400 grams were purchased from Charles River Laboratories, located in Wilmington, MA. All rats were maintained on a 2018 Teklad Global 18% Protein Rodent Diet (Harlan, San Diego, CA, USA) and water throughout the study period.

***Formulation Administration***

**[0067]** Food was removed from the cage the evening prior to surgery. Rats had ad lib access to drinking water while in the home cage the evening prior to surgery. During administration of

the formulations, rats were restrained and given 4 mL of Representative Formulation 1 or Comparative Formulation 1 by oral gavage. After administration of the test formulations, rats were returned to their home cage and given ad lib access to water. After a 3 hour period, the rats were prepared to undergo experimentally induced shock.

#### ***Anesthesia and Preoperative Preparation***

**[0068]** Animals were anesthetized with ketamine/xylazine (75/4 mg/kg, I.M.). Supplemental anesthesia (ketamine/xylazine 10 % initial dose, I.M.) was administered as indicated following response to tail/toe pinch. Anesthesia was maintained throughout the experimental shock period.

**[0069]** Rats were secured in a supine position to a temperature controlled (water circulating heat pump) operating table. The animals were maintained at 37 °C throughout the procedures.

**[0070]** All surgical procedures were performed using aseptic techniques. Sterile drapes, heat sterilized instruments, and surgical apparel (gown, face mask, and gloves) were used. The surgical sites on the abdomen and left groin were shaved and cleaned with betadine followed by 70% alcohol.

#### ***SMAO Procedures***

**[0071]** Following anesthetization, the superior mesentery artery was located and tied off (occluded) to prevent blood flow to the intestine and initiate a 30 minute shock/hypoperfusion period. The surgical site was covered with moistened sterile gauze during the entire SMAO shock period. After the 30 minute period, the SMAO was untied (occlusion removed). Perfusion was resumed for a period of 2 hours, followed by sacrifice of the animals.

#### ***Necropsy and Histological Processing***

**[0072]** The intestines were then harvested by tying off both ends, injecting a 10% neutral buffered formalin solution with a 30 gauge needle, and storing the intestine in a jar filled with 10% neutral buffered formalin.

**[0073]** Following at least 24 hours of incubation in formalin, an approximate 5 cm by 5 cm section of the ileum (at approximately 5/6 the length of the small intestine) was excised for structural analysis. The tissue sample was adhered to a cardboard backing and mounted for sectioning. Intestinal cross sections of 15-20 microns thickness were created on a Vibratome Series 3000 sectioning system. Free floating sections were washed overnight in water to remove formalin. Sections were then free floating stained with Alcian blue (pH 2.5) (Diagnostic

BioSystems, Catalog No. KT 003) and mounted on slides for analysis.

### ***Tissue Analysis***

**[0074]** A Leitz Wetzlar Dialux 20 microscope (Wetzlar, West Germany) and 20X objective was used to image tissue sections. Still images of the tissue were captured with a Spot Insight Gigabit Camera, Model No. 35.2, Diagnostic Instruments, Inc. (Sterling Heights, Michigan) and included software. Images were stored as TIFF files with no compression used. Images were loaded into Photoshop Elements 13 and enhanced to sharpen the contours of the villi. To quantify the extent of damage to the villi, villi were classified as damaged when either of the following criteria was met:

1. 1) Villi tips were broken away or structural damage to any portion of the villi; or
2. 2) Goblet cells (normally stained blue) were practically non-existent (<3 goblet cells with no stain) from the base to the villi tip

**[0075]** The Photoshop Text tool was used to place an n (for no damage) or a d (for damage) in proximity to each individual villi for each tissue cross section. Where a determination of damage was inconclusive, the villi were excluded from the analysis. These inconclusive villi were less than 5% of the total villi analyzed. An image demonstrating the identification methodology is in **Figure 1**, which shows a cross section of the small intestine from a rat treated with an enteral formulation. Healthy villi are marked with n and damaged villi are marked with d.

### ***Results***

**[0076]** A total of eight rats were tested. Four received Representative Formulation 1 by oral gavage, and four rats received Comparative Formulation 1 by oral gavage. Representative micrographs of the villi after administration of the formulations and shock induction are shown in **Figures 2A and 2B**. **Figure 2A** shows a cross section of the small intestine of a rat treated with Representative Formulation 1. The villi in **Figure 2A** appear healthy and structurally intact as the entire length of the villi are visible and completely covered in goblet cells. **Figure 2B** shows a cross section of the small intestine of a rat treated with Comparative Formulation 1. The villi in **Figure 2B** appear to be structurally damaged with missing villi tips and atypical goblet cell staining.

**[0077]** Quantification of villi that were structurally intact after administration of the formulations and shock induction are shown in **Tables 4 and 5** and **Figure 3**. **Table 4** shows the individual rat data for the quantification of the structurally intact villi. **Table 5** summarizes the total intact villi and damaged villi observed after administration of the formulations and shock induction.

Figure 3 shows the mean percentage of villi intact per rat after administration of the formulations and shock induction. 92.6% of villi were intact across all rats that received Representative Formulation 1, whereas only 52.8% of the villi were intact across all rats that received Comparative Formulation 1. These results are consistent with the mean values calculated from the total villi observed in Table 5.

**Table 4**

Rats Treated with Representative Formulation 1	% Intact Villi	Rats Treated with Comparative Formulation 1	% Intact Villi
Rat #11	90.9%	Rat #12	50.9%
Rat #13	90.2%	Rat #15	48.9%
Rat #14	91.3%	Rat #16	48.8%
Rat #18	97.9%	Rat #17	62.5%
Mean	92.6%	Mean	52.8%
SEM (+/-)	1.8%	SEM (+1-)	3.3%

**Table 5**

	Rat Treated with Representative Formulation 1	Rat Treated with Comparative Formulation 1
Number of Intact Villi	176	94
Number of Damaged Villi	14	85
Total Villi	190	179
% Intact	92.6%	52.5%

**Example 3: SMAO Shock Studies with Formulations Administered via Direct Enteral Injection**

**[0078]** The SMAO model was used to assess the ability of a representative composition comprising glucose (Representative Formulation 2) and a comparative composition without glucose (Comparative Formulation 2) to preserve the structural integrity of the gastrointestinal tract under ischemic conditions when administered by direct enteral injection. Formulation Preparation

**[0079]** The materials used to prepare the formulations and their sources are shown in **Table 6**. All materials used were USP grade. As shown in **Table 6**, the Representative Formulation 2 comprises tranexamic acid, electrolytes, PEG 3350, and glucose, and Comparative Formulation 2 comprises tranexamic acid, electrolytes, and PEG 3350.

**Table 6**

Component	Representative Formulation 1	Comparative Formulation 1	Source
Tranexamic Acid	0.182 g	0.182 g	Daiichi Sankyo
PEG 3350	1.222 g	1.222 g	OTC clinical grade Miralax
Sodium Sulfate (Anhydrous)	0.138 g	0.138 g	Sigma-Aldrich
Sodium Bicarbonate	0.041 g	0.041 g	Sigma-Aldrich
Sodium Chloride	0.036 g	0.036 g	Sigma-Aldrich
Potassium Chloride	0.017 g	0.017 g	Sigma-Aldrich
Glucose	0.971 g	0.0 g	Sigma-Aldrich
Water	15.412 g	15.412 g	Sterile water for injection
Total Solution	17.000 mL	17.000 mL	

#### ***Rats and Diet***

**[0080]** Male WISTAR rats with a weight of 360-400 grams were purchased from Charles River Laboratories, located in Wilmington, MA. All rats were maintained on a 2018 Teklad Global 18% Protein Rodent Diet (Harlan, San Diego, CA, USA) and water throughout the study period.

#### ***Formulation Administration***

**[0081]** Food was removed from the cage the evening prior to surgery. Rats had ad lib access to drinking water while in the home cage the evening prior to surgery. Following anesthesia, an incision was made in the midline of the abdomen for isolation of the small intestine. Rats were administered 17 mL of either Representative Formulation 2 or Comparative Formulation 2 via direct injection into the intestine using a 30 gauge needle. Following formulation administration, the rats were subjected to experimentally induced shock via the SMAO procedure.

#### ***Anesthesia and preoperative preparation***

**[0082]** Animals were anesthetized with ketamine/xylazine (75/4 mg/kg, I.M.). Supplemental anesthesia (ketamine/xylazine 10 % initial dose, I.M.) was administered as indicated following response to tail/toe pinch. Anesthesia was maintained throughout the experimental shock period.

**[0083]** Rats were secured in a supine position to a temperature controlled (water circulating heat pump) operating table. The animals were maintained at 37 °C throughout the procedures.

**[0084]** All surgical procedures were performed using aseptic techniques. Sterile drapes, heat sterilized instruments, and surgical apparel (gown, face mask, and gloves) were used. The surgical sites on the abdomen and left groin were shaved and cleaned with betadine followed by 70% alcohol.

#### ***SMAO Procedures***

**[0085]** To initiate the model, following anesthesia the superior mesentery artery was located and tied off (occluded) to prevent blood flow to the intestine and initiate a 30 minute shock/hypoperfusion period. The surgical site was covered with moistened sterile gauze during the entire SMAO shock period. After the 30 minute period, the SMAO was untied (occlusion removed). Perfusion was resumed for a period of 2 hours, followed by sacrifice of the animals.

#### ***Necropsy and Histological Processing***

**[0086]** The intestines were then harvested by tying off both ends, injecting a 10% neutral buffered formalin solution with a 30 gauge needle, and storing the intestines in a jar filled with 10% neutral buffered formalin.

**[0087]** Following at least 24 hours of incubation in formalin, an approximate 5 cm by 5 cm section of the ileum (at approximately 5/6 the length of the small intestine) was excised for structural analysis. The tissue sample was adhered to a cardboard backing and mounted for sectioning. Intestinal cross sections of 15-20 microns thickness were created on a Vibratome Series 3000 sectioning system. Free floating sections were washed overnight in water to remove formalin. Sections were then free floating stained with Alcian blue (pH 2.5) (Diagnostic BioSystems,Catalog No. KT 003) and mounted on slides for analysis.

#### ***Tissue Analysis***

**[0088]** A Leitz Wetzlar Dialux 20 microscope (Wetzlar, West Germany) and 20X objective was used to image tissue sections. Still images of the tissue were captured with a Spot Insight Gigabit Camera, Model No. 35.2, Diagnostic Instruments, Inc. (Sterling Heights, Michigan) and included software. Images were stored as TIFF files with no compression used. Images were loaded into Photoshop Elements 13 and enhanced to sharpen the contours of the villi. To quantify the extent of damage to the villi, villi were classified as damaged when either of the following criteria were met:

1. 1) Villi tips were broken away or structural damage to any portion of the villi; or
2. 2) Goblet cells (normally stained blue) were practically non-existent (<3 goblet cells with no stain) from the base to the villi tip

**[0089]** The Photoshop Text tool was used to place an n (for no damage) or a d (for damage) in proximity to each individual villi for each tissue cross section. Where a determination of damage was inconclusive, the villi were excluded from the analysis. These inconclusive villi were less than 5% of the total villi analyzed. An image demonstrating the identification methodology is in **Figure 1**, which shows a cross section of the small intestine from a rat treated with an enteral formulation. Healthy villi are marked with n and damaged villi are marked with d.

### **Results**

**[0090]** A total of eight rats were tested. Four rats received Representative Formulation 2 by direct enteral injection, and four rats received Comparative Formulation 2 by direct enteral injection. Representative micrographs of the villi after administration of the formulations and shock induction are shown in **Figures 4A** and **4B**. **Figure 4A** shows a cross section of the small intestine of a rat treated with Representative Formulation 2. The villi in **Figure 4A** appear healthy and structurally intact as the entire length of the villi are visible and completely covered in goblet cells. **Figure 4B** shows a cross section of the small intestine of a rat treated with Comparative Formulation 2. The villi in **Figure 4B** appear to be structurally damaged with missing villi tips and atypical goblet cell staining.

**[0091]** Quantification of villi that are structurally intact after administration of the formulations and shock induction are shown in **Tables 7** and **8** and **Figure 5**. **Table 7** shows the individual rat data for the quantification of the structurally intact villi. **Table 8** summarizes the total intact villi and damaged villi observed after administration of the formulations and shock induction. **Figure 5** shows the mean percentage of villi intact per rat after administration of the formulations and shock induction. 83.4% of villi were intact across all rats that received Representative Formulation 2, whereas only 51.3% of the villi were intact across all rats that received Comparative Formulation 2. These results are consistent with the mean values calculated from the total villi observed in Table 8.

**Table 7**

<b>Rats Treated with Representative Formulation 2</b>	<b>% Intact Villi</b>	<b>Rats Treated with Comparative Formulation 2</b>	<b>% Intact Villi</b>
Rat #1	85.3%	Rat #2	46.3%
Rat #4	88.2%	Rat #3	54.1%
Rat #6	76.0%	Rat #5	51.3%

Rats Treated with Representative Formulation 2	% Intact Villi	Rats Treated with Comparative Formulation 2	% Intact Villi
Rat #8	84.2%	Rat #7	53.7%
Mean	83.4%	Mean	51.3%
SEM (+/-)	2.6%	SEM (+/-)	1.8%

**Table 8**

	Rats Treated with Representative Formulation 2	Rats Treated with Comparative Formulation 2
Number of Intact Villi	110	106
Number of Damaged Villi	21	102
Total Villi	131	208
% Intact	84.0%	51.0%

***Example 4: Hemorrhagic Shock Studies with Formulations Administered via Direct Stomach Injection***

**[0092]** The hemorrhagic shock model was used to assess the ability of a representative composition comprising PEG 3350 (Representative Formulation 3) and a comparative composition without PEG 3350 (Comparative Formulation 3) to preserve the structural integrity of the gastrointestinal tract under hemorrhagic conditions when administered by direct stomach injection.

***Formulation Preparation***

**[0093]** The materials used to prepare the formulations and their sources are shown in **Table 9**. All materials used were USP grade. As shown in **Table 9**, the Representative Formulation 3 comprises tranexamic acid, electrolytes, PEG 3350, and glucose, and Comparative Formulation 3 comprises tranexamic acid, electrolytes, and glucose.

**Table 9**

Component	Representative Formulation 3	Comparative Formulation 3	Source
Tranexamic Acid	0.043 g	0.043 g	Daiichi Sankyo
PEG 3350	0.287 g	0.0 g	OTC clinical grade Miralax
Sodium Sulfate	0.033 g	0.033 g	Sigma-Aldrich

Component	Representative Formulation 3	Comparative Formulation 3	Source
(Anhydrous)			
Sodium Bicarbonate	0.010 g	0.010 g	Sigma-Aldrich
Sodium Chloride	0.009 g	0.009 g	Sigma-Aldrich
Potassium Chloride	0.004 g	0.004 g	Sigma-Aldrich
Glucose	0.229 g	0.229 g	Sigma-Aldrich
Water	3.629 g	3.629 g	Sterile water for injection
Total Solution	4.0000 mL	4.0000 mL	

***Rats and Diet***

**[0094]** Male WISTAR rats with a weight of 320-400 grams were purchased from Charles River Laboratories, located in Wilmington, MA. All rats were maintained on Charles River Laboratories feed and provided water ad libitum throughout the study period.

***Formulation Administration***

**[0095]** Food was removed from the cage the evening prior to surgery. After placement of catheters, a small skin incision in the abdomen was made for isolation of the stomach. Following stabilization after experimentally induced shock via the hemorrhagic shock procedure, rats were administered 4 mL of either Representative Formulation 3 or Comparative Formulation 3 via a direct injection into the middle of the stomach.

***Anesthesia and preoperative preparation***

**[0096]** Animals were anesthetized with ketamine (75 mg/kg, I.M.). Anesthesia was maintained throughout the experimental shock period.

**[0097]** Rats were secured in a supine position to a temperature controlled (water circulating heat pump) operating table. The animals were maintained at 37 °C throughout the procedures. Vital signs (systemic blood pressure or respiratory rate, body temperature) were monitored throughout the procedures.

**[0098]** All surgical procedures were performed using aseptic techniques. Sterile drapes, heat sterilized instruments, and surgical apparel (gown, face mask, and gloves) were used. The

surgical sites on the abdomen and left groin were shaved and cleaned with betadine followed by 70% alcohol.

#### ***Hemorrhagic Shock Procedures***

**[0099]** To initiate the model, rats were anesthetized with ketamine (75 mg/kg, I.M.). Abdominal and inguinal regions were shaved and disinfected with alcohol. The right femoral artery was cannulated. The surgical site was covered with moistened sterile gauze during entire hemorrhagic shock period. Hemorrhagic shock was initiated by reduction of blood volume (about 40% of whole blood volume based on 6% body weight) to achieve a blood pressure of 4.67 kPa (35 mmHg) (47.58 cm H<sub>2</sub>O) for a period of 2 hours. Briefly, each rat was heparinized with minimal concentrations of sodium heparin (0.5 USP units/ml of blood volume estimated as 6% body weight) to prevent blood coagulation during the procedure. The right femoral artery was connected with a 10 mL (10 cc) syringe. About 6 ml of blood was withdrawn from the femoral artery over a period of about 5-10 minutes. The syringe was then placed at 47.58 cm high above the rat body level. The syringe served as a blood reservoir that regulated blood pressure at 47.58 cm H<sub>2</sub>O (4.67 kPa (35 mm Hg)) automatically. If the blood pressure was above 47.58 cm H<sub>2</sub>O, blood flowed into the blood reservoir. If the blood pressure was under 47.58 cm H<sub>2</sub>O, the blood from the blood reservoir was infused into blood stream circulation. Once mean arterial pressure (MAP) was stabilized, either Representative Formulation 3 or Comparative Formulation 3 was injected into the middle of the stomach.

#### ***Necropsy and Histological Processing***

**[0100]** The intestines were then harvested by tying off both ends, injecting a 10% neutral buffered formalin solution with a 30 gauge needle, and storing the intestines in a jar filled with 10% neutral buffered formalin.

**[0101]** Following at least 24 hours of incubation in formalin, an approximate 5 cm by 5 cm section of the ileum (at approximately 5/6 the length of the small intestine) was excised for structural analysis. The tissue sample was adhered to a cardboard backing and mounted for sectioning. Intestinal cross sections of 15-20 microns thickness were created on a Vibratome Series 3000 sectioning system. Free floating sections were washed overnight in water to remove formalin. Sections were then free floating stained with Alcian blue (pH 2.5) (Diagnostic BioSystems, Catalog No. KT 003) and mounted on slides for analysis.

#### ***Tissue Analysis***

**[0102]** A Leitz Wetzlar Dialux 20 microscope (Wetzlar, West Germany) and 20X objective was

used to image tissue sections. Still images of the tissue were captured with a Spot Insight Gigabit Camera, Model No. 35.2, Diagnostic Instruments, Inc. (Sterling Heights, Michigan) and included software. Images were stored as TIFF files with no compression used. Images were loaded into Photoshop Elements 13 and enhanced to sharpen the contours of the villi. To quantify the extent of damage to the villi, villi were classified as damaged when either of the following criteria were met:

1. 1) Villi tips were broken away or structural damage to any portion of the villi; or
2. 2) Goblet cells (normally stained blue) were practically non-existent (<3 goblet cells with no stain) from the base to the villi tip

**[0103]** The Photoshop Text tool was used to place an n (for no damage) or a d (for damage) in proximity to each individual villi for each tissue cross section. Where a determination of damage was inconclusive, the villi were excluded from the analysis. These inconclusive villi were less than 5% of the total villi analyzed. An image demonstrating the identification methodology is in **Figure 1**, which shows a cross section of the small intestine from a rat treated with an enteral formulation. Healthy villi are marked with n and damaged villi are marked with d.

### **Results**

**[0104]** A total of eight rats were tested. Four rats received Representative Formulation 3 by direct stomach injection, and four rats received Comparative Formulation 3 by direct stomach injection. Representative micrographs of the villi after administration of the formulations and shock induction are shown in **Figures 6A** and **6B**. **Figure 6A** shows a cross section of the small intestine of a rat treated with Representative Formulation 3. The villi in **Figure 6A** appear healthy and structurally intact as the entire length of the villi are visible and completely covered in goblet cells. **Figure 6B** shows a cross section of the small intestine of a rat treated with Comparative Formulation 3. The villi in **Figure 6B** appear to be structurally damaged.

**[0105]** Quantification of villi that are structurally intact after administration of the formulations and shock induction are shown in **Tables 10** and **11** and **Figure 7**. **Table 10** shows the individual rat data for the quantification of the structurally intact villi. **Table 11** summarizes the total intact villi and damaged villi observed after administration of the formulations and shock induction. **Figure 7** shows the mean percentage of villi intact per rat after administration of the formulations and shock induction. 88.8% of villi were intact across all rats that received Representative Formulation 3, whereas only 64.1% of the villi were intact across all rats that received Comparative Formulation 3. These results are consistent with the mean values calculated from the total villi observed in Table 11.

### **Table 10**

Rats Treated with Representative Formulation 3	% Intact Villi	Rats Treated with Comparative Formulation 3	% Intact Villi
Rat #701	90.7%	Rat #802	65.6%
Rat #704	83.3%	Rat #805	66.7%
Rat #705	91.1%	Rat #806	62.7%
Rat #706	90.0%	Rat #807	61.5%
Mean	88.8%	Mean	64.1%
SEM (+1-)	1.8%	SEM (+1-)	1.2%

**Table 11**

	Rats Treated with Representative Formulation 3	Rats Treated with Comparative Formulation 3
Number of Intact Villi	171	105
Number of Damaged Villi	23	59
Total Villi	194	164
% Intact	88.1%	64.0%

***Example 5: Clinical Study for the Treatment of Septic Shock Primary Objective***

**[0106]** This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase 2 clinical study of septic shock patients to determine whether enteral administration of a formulation comprising tranexamic acid, PEG, glucose, and one or more electrolytes increases the number of days alive without cardiovascular, pulmonary, or renal replacement therapy through Day 28 compared to Placebo.

***Secondary Objectives***

**[0107]** The secondary safety objective of this study is to assess safety and tolerability of experimental composition in patients with septic shock.

***Eligibility***

**[0108]**

1. First episode of documented or suspected sepsis of peritoneal/abdominal, soft tissue,

blood, or community acquired lung origin.

2. 2. Must have septic shock requiring vasopressors despite adequate fluid resuscitation of 30 mL/kg crystalloid or colloid equivalent, for either an SBP <12 kPa (90 mmHg) or a MAP <8.67 kPa (65 mmHg) (i.e. must have been unable to maintain adequate blood pressure despite adequate fluid resuscitation).
3. 3. Age 18 to 75 years

### ***Study Design***

**[0109]** The study is composed of four periods:

- Screening: This period begins when the patient has documented or suspected sepsis of peritoneal/abdominal, soft tissue, blood, or community acquired lung origin and is unable to maintain adequate blood pressure (BP, systolic BP [SBP] >12 kPa (90 mmHg) or a mean arterial pressure [MAP] >65 without vasopressor support) despite intravenous fluid resuscitation. Enteral study drug administration must start within 4 hours of randomization and no later than 24 hours after the onset of shock.
- Intervention: This period begins with the first administration of the test formulation or placebo and continues throughout treatment duration, up to 8 days pending patient refusal to take study drug, exit from hospital or death. There are no food or fluid restrictions. However, during the first 48 hours following enrollment, physicians are encouraged to delay enteral nutrition. If a patient is moved from ICU and still in the hospital, study drug administration should continue until 8 doses have been administered.
- Post-intervention: This period begins after study drug administration is complete and continues through Study Day 28 or until the patient is discharged from the hospital (if before Day 28). If a patient has been discharged from the study hospital before Study Day 28, site personnel will contact the patient or surrogate, caregiver, family member, physician, or healthcare facility to obtain the patient's survival status, organ support and functional outcome assessment.
- Follow-up: Site personnel will contact the patient, surrogate, caregiver, family member, or patient's other healthcare providers to determine survival status on Day

**[0110]** All randomized patients will be divided between the two treatment arms in a 1:1 ratio stratified by highest total SOFA score during the screening period (known at the time of randomization); and then by percent change in serum lactate between the first and subsequent lactate measurements (separated by at least 4 hours to be used to qualify for randomization).

**[0111]** A total of 250 patients are enrolled. The 700 mL aqueous solution formulation shown in Table 2 is administered orally or via a nasogastric, orogastric, nasojejunal, orojejunal,

nasoduodenal, or percutaneous endoscopic gastrostomy tube or catheter to patients in the experimental arm. Patients in the placebo arm of the study receive 700 mL of a placebo solution that does not comprise tranexamic acid orally or via a nasogastric, orogastric, nasojejunal, orojunal, nasoduodenal, or percutaneous endoscopic gastrostomy tube or catheter. Daily treatment is administered continuously or intermittently spread over an 8 to 24 hour period. 700 mL of experimental product or placebo is administered every 24 hours. Treatment is administered daily on Study Days 1-8, barring death or hospital discharge. Depending on the start time of the initial administration (infusion) on Study Day 1, the final administration extends into Study Day 9.

### ***Efficacy Endpoints***

**[0112]** The primary efficacy endpoint is the number of days alive without cardiovascular, renal, or pulmonary organ support through Day 28. Patients are classified as having organ support if organ support is required through the use of:

- Mechanical ventilation;
- Vasopressors to maintain adequate BP, or
- Renal replacement therapy.

**[0113]** The secondary efficacy endpoint is mortality rate: Date of death will be recorded for all patients who have died on or before Study Day 90. The 7-day, 28-day, and 90-day mortality and survival rates will be evaluated.

### ***Results***

**[0114]** The aqueous solution formulation shown in Table 2 is safe and well-tolerated by patients in the experimental arm. Patients in the experimental arm exhibit an increase in the number of days without cardiovascular, renal, or pulmonary support through Day 28 of the study as compared to patients in the placebo arm. Patients in the experimental arm exhibit a decrease in the rates of mortality on day 90 of the study as compared to mortality rates of patients in the placebo arm.

***Example 6: Clinical Study for the Treatment of Shock and Multiorgan Dysfunction after Cardiovascular Surgery***

### ***Primary Objective***

**[0115]** This is a multicenter, randomized, double-blind, parallel, placebo-controlled, Phase 2 clinical study to determine whether enteral administration of a formulation comprising tranexamic acid, PEG, glucose, and one or more electrolytes prior to high risk cardiovascular surgery increases the number of days alive without cardiovascular, renal, or pulmonary dysfunction through Day 14 compared to Placebo.

#### ***Study Design***

**[0116]** All high risk cardiovascular surgery randomized patients will be divided between the 2 treatment groups in a 1:1 ratio stratified by:

- Age (<64 or >65 years of age);
- STS Cardiac Score, and
- Procedure.

**[0117]** The study is composed of four periods:

- Screening and randomization (not to exceed 4 weeks): prior to cardiovascular surgery.
- Intervention: will begin with the first enteral administration of study drug 6-12 hours prior to surgery (Day 0). Treatment should continue for a minimum of 7 days (pending patient refusal to take study drug, exit from hospital, or mortality). In some cases, patients with continued organ dysfunction remain on study drug for up to 10 days as long as organ dysfunction persists.
- Post-intervention in-hospital: will start after study drug administration is stopped (Day 8) and will continue through Day 14 or until the patient is discharged from the hospital.
- Follow-up: the patient will be contacted by phone to assess functional outcomes at Day 28.

**[0118]** A total of 100 patients are enrolled. The 700 mL aqueous solution formulation shown in Table 2 or a Placebo that does not comprise tranexamic acid is administered orally or via a nasogastric, orogastric, nasojejunal, orojejunal, nasoduodenal, or percutaneous endoscopic gastrostomy tube or catheter to patients on Days 0-7. If a patient continues to demonstrate organ dysfunction, the physician will continue treatment for a maximum of 10 days for some cases. Patients, investigators, persons performing the assessments, and data analysts remain blinded to the identity of the treatment from time of randomization until database lock.

#### ***Efficacy Endpoints***

**[0119]** The primary efficacy endpoint is the number of days alive without cardiovascular, renal or pulmonary organ support through Day 14. Patients are classified as requiring organ support if organ support is provided through the use of:

- Mechanical ventilation;
- Vasopressors to maintain adequate blood pressure (BP); or
- Renal replacement therapy (hemodialysis, peritoneal dialysis or continuous venous hemofiltration).

**[0120]** The secondary efficacy endpoint is mortality rate: date of death will be recorded for all patients who have died on or before Study Day 28 and Day 90. The 28-day and 90-day mortality and survival rates will be evaluated.

### ***Results***

**[0121]** The aqueous solution formulation shown in Table 2 is safe and well-tolerated by patients in the experimental arm. Patients in the experimental arm exhibit an increase in the number of days alive without cardiovascular, renal, or pulmonary dysfunction through Day 14 compared to Placebo. Patients in the experimental arm exhibit a decrease in the rates of mortality on day 90 of the study as compared to mortality rates of patients in the placebo arm.

**[0122]** While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only.

## **REFERENCES CITED IN THE DESCRIPTION**

### **Cited references**

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

### **Patent documents cited in the description**

- US61970247 [0001]
- US62019007 [0001]

**Non-patent literature cited in the description**

- **FRANK A. DELANO et al.** Pancreatic Digestive Enzyme Blockade in the Small Intestine Prevents Insulin Resistance in Hemorrhagic ShockSHOCK, US, 2014, vol. 41, 155-61 [0003]

Patentkrav

1. Vandig sammensætning omfattende ca. 6,8 gram til ca. 8,3 gram tranexamsyre, ca. 29,3 gram til ca. 35,8 gram polyethylenglycol, ca. 25 gram til ca. 31 gram glucose og én eller flere elektrolytter, hvor den vandige sammensætning er formuleret i en mængde på:
  - (i) ca. 630 mL til ca. 770 mL eller
  - (ii) ca. 700 mL,hvor termen "ca." betyder  $\pm 10\%$  af hver numerisk værdi.
- 10 2. Vandig sammensætning ifølge krav 1, hvor sammensætningen omfatter ca. 7,5 g tranexamsyre og ca. 28 g glucose, hvor termen "ca." betyder  $\pm 10\%$  af hver numerisk værdi.
3. Vandig sammensætning ifølge krav 1, hvor sammensætningen omfatter ca. 32,5 g polyethylenglycol; eventuelt hvor sammensætningen omfatter ca. 7,5 g tranexamsyre og ca. 15 32,5 g PEG 3350, hvor termen "ca." betyder  $\pm 10\%$  af hver numerisk værdi.
4. Vandig sammensætning ifølge et hvilket som helst af kravene 1-3, hvor den ene eller flere elektrolytter omfatter:
  - (I) ca. 3,6 gram til ca. 4,4 gram natriumsulfat, for eksempel ca. 4,0 g natriumsulfat, 20 eller
  - (ii) ca. 1,1 gram til ca. 1,3 gram natriumbicarbonat, for eksempel ca. 1,3 gram natriumbicarbonat; eller
  - (iii) ca. 0,9 gram til ca. 1,1 gram natriumchlorid, for eksempel ca. 1,0 g natriumchlorid; eller
  - 25 (iv) ca. 0,4 gram til ca. 0,6 gram kaliumchlorid, for eksempel ca. 0,5 g kaliumchlorid,hvor termen "ca." betyder  $\pm 10\%$  af hver numerisk værdi.
5. Vandig sammensætning ifølge et hvilket som helst af kravene 1-4, hvor 30 polyethylenglycolet er polyethylenglycol 3350.
6. Vandig sammensætning ifølge krav 1 omfattende ca. 7,5 g tranexamsyre, ca. 32,5 g PEG 3350, ca. 28 g glucose, ca. 4,0 g natriumsulfat, ca. 1,2 g natriumbicarbonat, ca. 1,0 g natriumchlorid og ca. 0,5 g kaliumchlorid;

eventuelt hvor den vandige sammensætning omfatter 7,5 g tranexamsyre, 32,5 g PEG 3350, 28 g glucose, 4,0 g natriumsulfat, 1,2 g natriumbicarbonat, 1,0 g natriumchlorid og 0,5 g kaliumchlorid;

5

hvor termen "ca." betyder  $\pm 10\%$  af hver numerisk værdi.

7. Vandig sammensætning ifølge et hvilket som helst af kravene 1-6 formuleret i en mængde på ca. 700 mL, hvor termen "ca." betyder  $\pm 10\%$  af den numeriske værdi.

10

8. Sammensætning omfattende sammensætning A eller sammensætning B:

Bestanddel	Sammensætning A Mængde (g)	Sammensætning B Mængde (g)
Tranexamsyre	7,8 $\pm 10\%$	7,5 $\pm 10\%$
PEG 3350	50,3 $\pm 10\%$	32,5 $\pm 10\%$
Natriumsulfat	5,7 $\pm 10\%$	4,0 $\pm 10\%$
Natriumbicarbonat	1,7 $\pm 10\%$	1,2 $\pm 10\%$
Natriumchlorid	1,5 $\pm 10\%$	1,0 $\pm 10\%$
Kaliumchlorid	0,7 $\pm 10\%$	0,5 $\pm 10\%$
Glucose	40 $\pm 10\%$	28 $\pm 10\%$

hvor sammensætning A rekonstitueres i vand til 1000 mL,

hvor sammensætning B rekonstitueres i vand til 700 mL.

15

9. Sammensætning ifølge et hvilket som helst af kravene 1-8 til anvendelse i behandling af shock, autodigestion, multiorgansvigt, intestinal iskæmi eller hypoperfusion.

10. Sammensætning til anvendelse ifølge krav 9, hvor sammensætningen er beregnet til 20 anvendelse i behandling af shock og shocket er:

**A:** hæmoragisk shock, septisk shock, kardiogent shock eller shock forbundet med eller forårsaget af en hæmoragisk virus, eventuelt hvor:

det hæmoragiske shock er forbundet med eller forårsaget af et traume, eller  
det septiske shock er forbundet med eller forårsaget af sepsis, eller  
det kardiogene shock er forbundet med eller forårsaget af kardiovaskulær kirurgi,  
myokardieinfarkt, arytmii eller mekaniske komplikationer, eller

5

**B:** hypovolæmisk shock, eventuelt hvor:

det hypovolæmiske shock er forbundet med eller forårsaget af traume, eller

det hypovolæmiske shock forbundet med eller forårsaget af ebolavirussygdom eller andet  
hæmoragisk virus.

10

11. Sammensætning ifølge et hvilket som helst af kravene 1-8 til anvendelse i bevaring af  
fordøjelseskanalens strukturelle integritet under iskæmiske eller hæmoragiske tilstande.

15

12. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 9-11, hvor  
sammensætningen indgives oralt.

13. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 9-12, hvor  
sammensætningen indgives via nasogastrisk, orogastrisk, nasojejunal, orojejunal, nasoduodenal  
eller percutan endoskopisk gastrostomislange eller kateter.

20

14. Kit, der omfatter:

(a) en første beholder, der omfatter tranexamsyre, polyethylenglycol og én eller flere  
elektrolytter,

(b) en anden beholder, der omfatter glucose, og

25 (c) instruktioner til kombination af den første beholder og den anden beholder for at  
danne en vandig sammensætning ifølge et hvilket som helst af kravene 1-8.

30 15. Kit ifølge krav 14, hvor den første beholder omfatter ca. 7,8 g tranexamsyre, ca. 50,3 g  
PEG 3350, ca. 5,7 g natriumsulfat, ca. 1,7 g natriumbicarbonat, ca. 1,5 g natriumchlorid og ca.  
0,7 g kaliumchlorid, og hvor den anden beholder omfatter ca. 40 g glucose; eventuelt hvor kittet  
endvidere omfatter instruktioner til rekonstitution af tranexamsyren, PEG 3350, glucose og én  
eller flere elektrolytter med vand til 1000 mL, hvor termen "ca." betyder  $\pm 10\%$  af hver numerisk  
værdi.

16. Kit ifølge krav 14, hvor den første beholder omfatter ca. 7,5 g tranexamsyre, ca. 32,5 g PEG 3350, ca. 4,0 g natriumsulfat, ca. 1,2 g natriumbicarbonat, ca. 1,0 g natriumchlorid og ca. 0,5 g kaliumchlorid, og hvor den anden beholder omfatter ca. 28 g glucose; eventuelt hvor kittet endvidere omfatter instruktioner til rekonstitution af tranexamsyren, PEG 3350, glucose og én eller flere elektrolytter med vand til 700 mL, hvor termen "ca." betyder  $\pm 10\%$  af hver numerisk værdi.

# DRAWINGS

**Figure 1**




Figure 2A




Figure 2B




Figure 3




Figure 4A




Figure 4B




Figure 5




Figure 6A




Figure 6B




Figure 7

